《大行報告》大摩下調同程旅行(00780.HK)目標價至18元 評級「增持」
摩根士丹利發表研究報告,指出截至3月9日,包括一線城市在內的內地本土疫情病例激增至400多宗,該行將同程旅行(00780.HK)2022至2023財年的收入及純利預測,分別下調7%至8%。
該行預期,同程旅行今年收入預測增長16%,至86億元人民幣,低過市場預期11%,主要由於Omicron在中國的傳播,令該行的預測較爲謹慎,同時預測經調整純利增長16%至14.8億元人民幣,較市場預期低6%。
此外,對於今年上半年,該行料首季同程旅行收入按季跌9%,並於第二季回覆至按季增長22%的水平,預期復甦預測基於內地於2月11日有條件批準新冠藥物Paxlovid進口註冊,發改委關於防止過度控制、不必要封鎖、交通中斷、對廣泛服務行業的幹擾,以及有傳內地計劃最早在今年夏天在選定的城市測試旅行泡沫。
大摩對同程旅行的目標價由20元下調至18元,評級「增持」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.